Abstract The immune response is regulated not only by the proliferation, differentiation, and activation of cells, but also by programmed cell death, called apoptosis. Fas ligand expressed in activated T cells binds to its receptor, Fas, and induces apoptosis in target cells. Two mouse mutations that cause autoimmune disease, lpr (lymphoproliferation) and gld (generalized lymphoproliferative disease), are mutations in Fas and FasL genes, respectively. Human patients showing phenotypes (Canale-Smith syndrome or autoimmune lymphoproliferative syndrome) similar to those in lpr mice also carry mutations in Fas. This is a good example of a case in which the identification of a mouse mutation has led to the understanding of a human disease.
Fas ligand and Fas
Cellular proliferation, differentiation, and apoptosis are regulated by a family of proteins called cytokines. Fas ligand (FasL) is a cytokine that belongs to the tumor necrosis factor (TNF) family (Nagata 1997; Nagata and Golstein 1995) . FasL is predominantly expressed in activated T lymphocytes and natural killer (NK) cells, and works as one of the effector molecules of these cytotoxic cells. FasL is synthesized as a type II membrane protein, and its extracellular region of about 150 amino acids is well conserved (20%-25%) among members of the TNF family. A metalloproteinase called TACE (TNF alpha converting enzyme) cleaves membrane-associated TNF to produce a soluble TNF (Black et al. 1997; Moss et al. 1997) . Similarly, membrane-bound FasL undergoes metalloproteinasemediated proteolytic cleavage to generate a soluble form of this cytokine (Tanaka et al. 1996) . The membrane-bound FasL is more active than soluble FasL in inducing apoptosis, suggesting that FasL works locally via cell-cell interactions under physiological conditions, and that the purpose of shedding FasL is to attenuate the process. The functional soluble form of human FasL exists as a trimer, suggesting that membrane-bound FasL also has the potential to form a trimeric structure.
Fas (also known as APO-1 or CD95), the receptor for FasL, is a type I membrane protein, and is expressed rather ubiquitously in various tissues (Nagata 1997; Nagata and Golstein 1995) . Fas is a member of the TNF receptor (TNFR) family, which includes two TNFRs (TNFR1 and TNFR2), DR3 (death receptor-3), DR-4, and DR-5. The extracellular region of the TNF receptor family members carries 2-6 repeats of a cysteine-rich subdomain that has about 25% similarity among its members. In contrast, there is little similarity among the cytoplasmic regions of the TNFR family members, except for Fas, TNFR1, DR-3, and DR-4. Binding of FasL to Fas, or cross-linking Fas with agonistic antibodies induces apoptosis in Fas-bearing cells (Itoh et al. 1991; Trauth et al. 1989; Yonehara et al. 1989) . TNF induces apoptosis mainly through TNFR1, although it can also activate the transcription factor NF-κB through this receptor (Vandenabeele et al. 1995) . The presence of a homologous domain (about 80 amino acids) in the cytoplasmic regions of Fas and TNFR1 suggests that this region is responsible for transducing the death signal. In fact, mutational analyses of Fas and TNFR1 indicated that this is the case, and this domain has been designated a death domain (Itoh and Nagata 1993; Tartaglia et al. 1993) . DR-3 and DR-4 also carry a death domain, and can transduce the apoptotic signal under some circumstances.
Fas and TNFR1 must be oligomerized to be activated. Xray diffraction analysis of the TNF -TNF receptor complex has indicated that a TNF trimer forms a complex with three TNF receptor molecules (Banner et al. 1993 ). This suggests that TNF induces trimerization of its receptor. The similarity between the structures of FasL and TNF, and between Fas and the TNF receptors suggest that FasL also induces trimerization of Fas, and that the trimerized cyto-plasmic region then transduces the signal. Fas-mediated apoptosis does not require RNA or protein synthesis (Itoh et al. 1991; Yonehara et al. 1989) , suggesting that all the components necessary for apoptotic signal transduction are already present in growing cells, and that Fas activation just triggers this machinery. An adaptor molecule called FADD (Fas-associated protein with death domain) or MORT1, which contains a death domain at its C-terminus (Boldin et al. 1995; Chinnaiyan et al. 1996) , is recruited to Fas upon its activation (Kischkel et al. 1995) and binds to Fas via interactions between the death domains. The N-terminal region [termed the death-effector domain (DED) or MORT1 domain] is responsible for the downstream signal transduction and binds caspase 8 (Boldin et al. 1996; Muzio et al. 1996) . Caspase 8 carries two DED/MORT1 domains in its N-terminal region, through which it binds FADD/MORT1. Thus, the Fas oligomerization induced by the binding of FasL results in the oligomerization of caspase 8, which probably causes the self-activation of its protease domain.
Caspases are a family of cysteine proteases consisting of two large (p17) and two small (p10) subunits, which are generated by the proteolytic cleavage of a larger precursor (a zymogen). The caspase family is comprised of at least 10 members, which are divided into three subgroups based on their substrate specificity (Alnemri et al. 1996; Thornberry et al. 1997) . All caspases cleave their substrates after aspartic acid, and cause apoptosis when overexpressed in cells. Inhibitors of caspase 1 or caspase 3 block Fas-induced apoptosis, which suggests that both caspase 1-and caspase 3-like proteases are involved in Fas-mediated apoptosis (Enari et al. 1996) . Monitoring the protease activity with fluorescent substrates specific for caspase 1 and caspase 3 demonstrates that a caspase 1-like protease is transiently activated, whereas the activation of a caspase 3-like protease gradually increases during Fas-induced apoptosis. The activation of the caspase 3-like protease is dependent on the activation of a caspase 1-like protease, indicating that these proteases are sequentially activated. It is likely that other members of the caspase family are also activated in the cascade, and these members cleave their "death substrates" such as lamin, actin, poly(ADP-ribose) polymerase, rho-GDI, SREBP, and DNA-dependent protein kinase, to cause the apoptotic morphological changes . We have recently identified a caspase-activated DNase (CAD) that is localized to the cytoplasm of growing cells . CAD seems to exist as a complex with ICAD (an inhibitor of CAD), which can be cleaved by caspase 3 ). Thus, apoptotic stimuli activate caspase, which cleaves and thus inactivates ICAD. ICAD inactivation allows the release of CAD, which can then enter nuclei to cleave the chromosomal DNA.
lpr and gld
The mouse mutations lpr (lymphoproliferation) and gld (generalized lymphoproliferative disease) are autosomal recessive mutations located on mouse chromosomes 19 and 1, respectively (Cohen and Eisenberg 1991) . There is another allelic mutation in the lpr locus, which was discovered in the CBA/k1 mouse strain (Matsuzawa et al. 1990 ). Since the mutated mice (lpr cg /ϩ, gld/ϩ) that are heterozygous for gld show a weak phenotype, the mutation was designated as lpr cg (for lpr complementing gld). Allen et al. (1990) performed a series of bone marrow transplantations among lpr, gld, and wild-type mice to establish the relationship between these defects. These analyses indicated that lpr and gld are mutations in two different proteins and, more specifically, that gld is a mutation of a soluble or membrane-bound cytokine, while lpr is a mutation of its receptor. As described below, we have identified the mutations in Fas and FasL in lpr and gld mice (Takahashi et al. 1994; Watanabe-Fukunaga et al. 1992) , thus verifying this proposal.
MRL-lpr or -gld mice develop lymphadenopathy and splenomegaly, and produce large amounts of antibodies, including anti-DNA antibody and rheumatoid factor (Cohen and Eisenberg 1991) . The mice die of nephritis or arthritis at approximately 5 months of age. Lymphocytes accumulate in the lymph nodes and spleen of lpr or gld mice, and this accumulation can be prevented by neonatal thymectomy. The accumulated lymhocytes express the Tcell marker Thy-1, and the B-cell marker B220. These cells also express a rearranged T-cell receptor, but not a rearranged IgG gene. Although CD4 and CD8, which are usually expressed in mature T cells, are not expressed in these lymphocytes, it is likely that they are derived from mature single positive CD4
ϩ T cells by suppressing the expression of CD4 or CD8.
The Fas gene maps to a location near the lpr locus of mouse chromosome 19, and Northern blot hybridization indicated that lpr mice express very little Fas mRNA (Watanabe-Fukunaga et al. 1992) . The Fas chromosomal gene is more than 70 kb in length and is split by 8 introns, whereas the mutated gene in lpr mice has an early transposable element (ETn), similar to an endogenous retrovirus, inserted into intron 2 (Fig. 1a) (Adachi et al. 1993) . Since the ETn carries poly(A) adenylation signals (AATAAA) in its long terminal repeat (LTR) sequences, it was assumed that the Fas transcript prematurely terminates in intron 2 and is aberrantly spliced. In fact, small mRNAs coding for exons 1 and 2 have been found in the thymus and liver of lpr mice. These results indicate that transcription of the gene encoding Fas is impaired in lpr mice. However, the inhibition of expression is not complete, as demonstrated by the presence of full-length Fas mRNA, albeit at a low level, in the thymus and liver of lpr mice, indicating that lpr is a leaky mutation. Unlike the lpr strain, lpr cg mice express full-length Fas mRNA as abundantly as wild-type mice (WatanabeFukunaga et al. 1992) . However, the mRNA carries a point mutation (T to A) in the middle of the Fas cytoplasmic region (Watanabe-Fukunaga et al. 1992 ). This mutation results in an amino acid change, from isoleucine to asparagine (Fig. 1a) , and abolishes the ability of Fas to transduce the apoptotic signal.
The murine gene for FasL maps close to the At-3 gene on chromosome 1 (Takahashi et al. 1994) , where the gld muta- Fig. 1a,b tion is localized. It has been shown that gld mice carry a point mutation near the C-terminus of the coding region for FasL (Fig. 1b) (Takahashi et al. 1994 ). This mutation results in the replacement of phenylalanine with leucine, and abolishes the ability of FasL to bind to Fas. These results indicate that mouse mutations lpr and gld are loss-of-function mutations of Fas and FasL, respectively. Fas-null mice, established by gene targeting (Adachi et al. 1995) , also show lymphadenopathy and splenomegaly which are more pronounced than in mice carrying the leaky lpr mutation, further confirming the above conclusion.
Physiological roles of Fas-induced apoptosis
Lymphocytes, which are responsible for removing virally infected and cancerous cells, die at various stages of their development. Most immature T cells are useless (due to incorrect rearrangement of the T-cell receptor) or potentially detrimental (self-reactive) to the organism. More than 95% of the thymocytes that immigrate into the thymus are eliminated by positive and negative selection during their development. In the periphery, mature T cells that recognize self antigens are also deleted (peripheral clonal deletion). When mature T cells encounter target cells, they are activated to proliferate. However, after the activated T cells accomplish their task, they must be removed to avoid accumulation.
Mature T cells from lpr or gld mice do not die upon activation (Russell et al. 1993) . When T-cell hybridomas are activated in the presence of a Fas-neutralizing molecule, they do not die (Brunner et al. 1995; Dhein et al. 1995; . These results indicate that Fas is involved in the activation-induced suicide of T cells, i.e., in the downregulation of the immune response (Nagata and Golstein 1995) . Peripheral clonal deletion may also be mediated by the Fas system, because the cells to be deleted in this process are activated by interactions with the cells expressing self antigens. Thymocytes abundantly express Fas, and they are sensitive to Fas-induced apoptosis. However, thymic clonal deletion is apparently normal in mice lacking the functional Fas system (lpr, gld or Fas-null mice) (Singer and Abbas 1994) . These results suggest that Fas is not involved in the deletion process in the thymus, although one cannot rule out the possibility that this process is mediated by redundant mechanisms or is modulated by Fas/FasL system (Castro et al. 1996) .
In addition to T cells, the Fas-deficient mice accumulate B cells and have elevated levels of immunoglobulins of various classes, which include anti-ssDNA and anti-dsDNA antibodies (Cohen and Eisenberg 1991) , suggesting an involvement of the Fas system in the deletion of activated or autoreactive B lymphocytes. In fact, the immunization of mice with antigens rapidly induces Fas expression in germinal centers. Furthermore, the activation of naive B cells through CD40 sensitizes them to Fas-mediated apoptosis, while their co-stimulation through CD40 and the Ig receptor makes them resistant (Rothstein et al. 1995) . Although these results suggest that FasL-expressing T cells kill the Fas-expressing activated B cells, the precise mechanism and physiological role of Fas in the deletion of B cells remains to be studied.
Fas mutations in human patients
The Canale-Smith syndrome, also called human lymphoproliferative syndrome and autoimmunity or autoimmune lymphoproliferative syndrome, is a rare disease that causes lymphadenopathy in children (Canale and Smith 1967) . Patients with the syndrome show lymphadenopathy, hepatosplenomegaly, and hypergammaglobulinemia within the first two years of life. Some patients also show autoimmune diseases such as hemolytic anemia, thrombocytopenia, and neutropenia, resulting from the production of autoantibodies against red blood cells and platelets. The cells accumulated in the lymph nodes and spleen comprise a usual population of nonmalignant T cells that have characteristics of CD4 Ϫ
CD8
Ϫ and TcR ϩ cells. These cells express high levels of HLA-DR and IL-2 receptor α-chain, suggesting that they are chronically activated T cells. Since these phenotypes are similar to those found in lpr or gld mice, many groups looked for abnormalities in the Fas gene of these patients. In fact, to date, seventeen alleles for Fas mutations accompanying this syndrome have been identified in France, USA, Italy, and Japan (Bettinardi et al. 1997; Drappa et al. 1996; Fisher et al. 1995; Kasahara et al. 1997; Le Deist et al. 1996; RieuxLaucat et al. 1995; Sneller et al. 1997) .
Among these mutant alleles in the human Fas gene, thirteen are mutations in the coding sequence (Fig. 2a) , while four are mutations in the splice junctions (Fig. 2b) . Deletion and insertion mutations, as well as non-sense mutations in the extracellular and cytoplasmic regions of the Fas gene result in the genes that code for truncated Fas molecules. One point mutation is found in the extracellular region, which probably abolishes its ligand-binding activity. Five point mutations are in the Fas cytoplasmic region (Fig.  3) , each of which causes a nonconservative amino acid replacement, and may abolish the ability of Fas to recruit the signal-transducing adaptor FADD. Two mutations are in splice junctions in intron 3, and these cause aberrant splicing of the region of the Fas transcript that codes for the soluble form of Fas. Other mutations in either intron 6 or 7 produce a Fas protein that lacks most of its cytoplasmic region.
The mouse lpr mutation is recessive, and mice carrying the heterozygous lpr or lpr cg mutation do not show the mutant phenotype (Cohen and Eisenberg 1991) . Accordingly, there are three examples of human patients carrying homozygous Fas mutations. Patients with a deletion mutation (Del-291) and a splice mutation in intron 2 carry the mutation as two alleles with identical lesions (Bettinardi et al. 1997; Kasahara et al. 1997) . These patients are born to parents who are first or second cousins, and the parents are heterozygous for the same mutation. In another example, three siblings of one family carry a mutation of "compound homozygocity," in which children carry the R-105 to W-105 mutation in one allele, and the Y-216 to C-216 mutation in the other allele. These mutations are inherited from the mother and father, respectively. All other patients seem to carry a heterozygous mutation in the Fas gene. Because Fas must be trimerized to transduce the signal, these molecules, which are truncated or bear a mutation in the cytoplasmic region, are postulated to behave in a dominant-negative manner (Fisher et al. 1995) . Fas truncated in the extracellular region (specifically truncated after exon 3) is postulated to work as a soluble form of Fas that can neutralize FasL. Although the above explanation is probably correct, it does not explain why abnormal phenotypes are not seen in the fathers or mothers of the patients, who also carry a heterozygous mutation in the Fas gene. The patients who show the disease phenotypes may carry mutations in other complementing genes. Alternatively, Fas may be required only during the perinatal period in humans.
Conclusions
The Canale-Smith syndrome results from a congenital mutation and is difficult to cure. Identifying a Fas mutation in patients suffering from this syndrome may help to establish proper treatment for them. In mice, Fas seems to be involved in the homeostasis of T cells at a certain stage of development. Thus, splenoectomy at two weeks of age markedly retards lymphoproliferation (Smathers et al. 1984) , and treatment of the affected animals at the age of 19 weeks with drugs such as DIAM4 reduces the autoimmune disease ). If Fas is required primarily in early human development, surgery on the enlarged lymph nodes and spleen may cure the disease in human patients. As mentioned above, the T cells that accumulate in lpr mice and human patients are activated T cells, and they express a high level of Fas ligand. When the bone-marrow cells of lpr mice are transferred to wild-type mice, the recipient mice undergo graft-versus-host-disease-like wasting syndrome, and quickly die (Theofilopoulos et al. 1985) . The disease is due to FasL expressed in T cells derived from lpr mice, which induces massive apoptosis in various tissues, because many cells in the wild-type recipients express functional Fas. We now know that many families carry a heterozygous mutation in the Fas gene without any obvious abnormal phenotype. If the other allele of the Fas gene is sporadically mutated in T lymphocytes, those T lymphocytes carrying the homozygous mutation may cause tissue destruction and wasting syndrome.
Identification of FasL and Fas as a death factor and its receptor, has led us to the discovery that the murine lpr and gld defects are mutations in the genes encoding Fas and FasL. This discovery has now led us to the identification of the molecular basis of a human disease. This is a prime example of a case in which a mouse disease model directly led to the understanding of analogous human diseases. Many groups are currently establishing mice lacking genes involved in apoptotic signal transduction. Phenotypes seen in these mice would certainly contribute to our knowledge of human diseases.
